ATE190840T1 - Zusammensetzung zur behandlung der parkinson- krankheit - Google Patents
Zusammensetzung zur behandlung der parkinson- krankheitInfo
- Publication number
- ATE190840T1 ATE190840T1 AT93923142T AT93923142T ATE190840T1 AT E190840 T1 ATE190840 T1 AT E190840T1 AT 93923142 T AT93923142 T AT 93923142T AT 93923142 T AT93923142 T AT 93923142T AT E190840 T1 ATE190840 T1 AT E190840T1
- Authority
- AT
- Austria
- Prior art keywords
- parkinson
- disease
- treatment
- composition
- antagonists
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010050012 Bradyphrenia Diseases 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001596 famotidine Drugs 0.000 abstract 1
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 1
- 229960000620 ranitidine Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/954,258 US5352688A (en) | 1991-02-14 | 1992-09-30 | Methods for the treatment of bradyphrenia in parkinson's disease |
| PCT/US1993/009191 WO1994007490A1 (en) | 1992-09-30 | 1993-09-27 | Method and composition for the treatment of parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE190840T1 true ATE190840T1 (de) | 2000-04-15 |
Family
ID=25495171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93923142T ATE190840T1 (de) | 1992-09-30 | 1993-09-27 | Zusammensetzung zur behandlung der parkinson- krankheit |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5352688A (de) |
| EP (1) | EP0665749B1 (de) |
| AT (1) | ATE190840T1 (de) |
| AU (1) | AU688739B2 (de) |
| CA (1) | CA2145521A1 (de) |
| DE (1) | DE69328186T2 (de) |
| DK (1) | DK0665749T3 (de) |
| IL (1) | IL107134A (de) |
| WO (1) | WO1994007490A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352688A (en) * | 1991-02-14 | 1994-10-04 | The Mount Sinai School Of Medicine Of The City University Of New York | Methods for the treatment of bradyphrenia in parkinson's disease |
| US5453428A (en) * | 1991-02-14 | 1995-09-26 | The Mount Sinai School Of Medicine Of The City Of New York | Method and composition for the treatment of apathy-amotivation syndrome |
| US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| CA2198457A1 (en) * | 1994-08-30 | 1996-03-07 | Koichi Kojima | Isoxazole derivatives |
| EP0861075A1 (de) * | 1995-11-13 | 1998-09-02 | Albany Medical College | Analgetische verbindungen und deren verwendung |
| ATE281178T1 (de) | 1997-07-25 | 2004-11-15 | Altana Pharma Ag | Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen |
| US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US20020198231A1 (en) * | 1999-07-13 | 2002-12-26 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease |
| US20040229908A1 (en) * | 1999-07-13 | 2004-11-18 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6780880B1 (en) * | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| HUP0002154A3 (en) * | 2000-06-06 | 2002-06-28 | Richter Gedeon Vegyeszet | Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression |
| DE102005044815A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
| US8058296B2 (en) * | 2008-11-25 | 2011-11-15 | Richard Tokunaga | Treatment and prevention of deleterious effects associated with alcohol consumption |
| CA2807661C (en) | 2010-08-11 | 2019-09-10 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
| WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
| EP3062791B1 (de) | 2013-10-28 | 2020-01-08 | Drexel University | Neuartige behandlung gegen aufmerksamkeits- und kognitionsstörungen und gegen mit neurodegenerativen erkrankungen assoziierte demenz |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG39661A1 (en) * | 1984-04-13 | 1986-08-29 | Ivanova | Antiulcer means |
| US4757060A (en) * | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
| US5070101A (en) * | 1991-02-14 | 1991-12-03 | Mount Sinai School Of Medicine Of The City University Of New York | Method and pharmaceutical composition for the treatment of schizophrenia |
| US5352688A (en) * | 1991-02-14 | 1994-10-04 | The Mount Sinai School Of Medicine Of The City University Of New York | Methods for the treatment of bradyphrenia in parkinson's disease |
-
1992
- 1992-09-30 US US07/954,258 patent/US5352688A/en not_active Expired - Lifetime
-
1993
- 1993-09-27 DE DE69328186T patent/DE69328186T2/de not_active Expired - Fee Related
- 1993-09-27 AT AT93923142T patent/ATE190840T1/de not_active IP Right Cessation
- 1993-09-27 EP EP93923142A patent/EP0665749B1/de not_active Expired - Lifetime
- 1993-09-27 AU AU52929/93A patent/AU688739B2/en not_active Ceased
- 1993-09-27 CA CA002145521A patent/CA2145521A1/en not_active Abandoned
- 1993-09-27 WO PCT/US1993/009191 patent/WO1994007490A1/en not_active Ceased
- 1993-09-27 DK DK93923142T patent/DK0665749T3/da active
- 1993-09-28 IL IL107134A patent/IL107134A/en not_active IP Right Cessation
-
1994
- 1994-09-28 US US08/314,414 patent/US5547969A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL107134A0 (en) | 1993-12-28 |
| DE69328186T2 (de) | 2000-12-21 |
| AU688739B2 (en) | 1998-03-19 |
| EP0665749A4 (de) | 1996-04-10 |
| EP0665749B1 (de) | 2000-03-22 |
| WO1994007490A1 (en) | 1994-04-14 |
| EP0665749A1 (de) | 1995-08-09 |
| IL107134A (en) | 1998-02-22 |
| DE69328186D1 (de) | 2000-04-27 |
| US5352688A (en) | 1994-10-04 |
| CA2145521A1 (en) | 1994-04-14 |
| AU5292993A (en) | 1994-04-26 |
| DK0665749T3 (da) | 2000-08-28 |
| US5547969A (en) | 1996-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE190840T1 (de) | Zusammensetzung zur behandlung der parkinson- krankheit | |
| SE9401406D0 (sv) | Pharmaceutical products for curing tumourous diseases and process for preparing same | |
| ATE348808T1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| KR880011197A (ko) | 위장장해를 치료하기 위한 조성물 및 방법 | |
| EP0444196A4 (en) | Agent for treatment and prophylaxis of ischemic disease of heart or brain | |
| CY1109191T1 (el) | Μια νεα χρηση της δεφεριπρονης | |
| RU94042907A (ru) | Производные имидазопиридина, способ их получения, фармацевтическая композиция и способ ее получения | |
| DE69521536D1 (de) | Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten | |
| ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
| DE69800859D1 (de) | Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen | |
| ES8400742A1 (es) | Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co. | |
| ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
| CA2534634A1 (en) | Azolidinecarbonitriles and their use as dpp-iv inhibitors | |
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| IL118833A (en) | Sertraline for use as a medicament in the treatment of post-myocardial infarction patients | |
| ATE193206T1 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| DE68901172D1 (de) | (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend. | |
| ATE207353T1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
| HUT62474A (en) | Process for producing veterinary composition with antiparasitic effect | |
| GR3032531T3 (en) | Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases | |
| ATE271867T1 (de) | Behandlung der harninkontinenz und zusammenstellung dafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |